544 related articles for article (PubMed ID: 15784036)
1. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
3. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
4. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
5. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
Kalambokis G; Fotopoulos A; Economou M; Pappas K; Tsianos EV
J Hepatol; 2007 Feb; 46(2):213-21. PubMed ID: 17156883
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
8. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R; Woodis CB
Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324
[TBL] [Abstract][Full Text] [Related]
9. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Singh V; Dhungana SP; Singh B; Vijayverghia R; Nain CK; Sharma N; Bhalla A; Gupta PK
J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
[TBL] [Abstract][Full Text] [Related]
10. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Singh V; Singh A; Singh B; Vijayvergiya R; Sharma N; Ghai A; Bhalla A
Am J Gastroenterol; 2013 Apr; 108(4):560-7. PubMed ID: 23419385
[TBL] [Abstract][Full Text] [Related]
11. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Pomier-Layrargues G; Paquin SC; Hassoun Z; Lafortune M; Tran A
Hepatology; 2003 Jul; 38(1):238-43. PubMed ID: 12830007
[TBL] [Abstract][Full Text] [Related]
12. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
Tandon P; Tsuyuki RT; Mitchell L; Hoskinson M; Ma MM; Wong WW; Mason AL; Gutfreund K; Bain VG
Liver Int; 2009 Feb; 29(2):169-74. PubMed ID: 18492024
[TBL] [Abstract][Full Text] [Related]
13. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
[TBL] [Abstract][Full Text] [Related]
14. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.
Sàbat M; Guarner C; Soriano G; Bulbena O; Novella MT; Ortiz J; Ricart E; Villanueva C; Rosello J; Rodríguez J; Balanzó J
Dig Dis Sci; 1998 Oct; 43(10):2184-9. PubMed ID: 9790452
[TBL] [Abstract][Full Text] [Related]
15. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
Ottesen LH; Aagaard NK; Kiszka-Kanowitz M; Rehling M; Henriksen JH; Pedersen EB; Flyvbjerg A; Bendtsen F
Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
17. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
[TBL] [Abstract][Full Text] [Related]
18. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Appenrodt B; Wolf A; Grünhage F; Trebicka J; Schepke M; Rabe C; Lammert F; Sauerbruch T; Heller J
Liver Int; 2008 Aug; 28(7):1019-25. PubMed ID: 18410283
[TBL] [Abstract][Full Text] [Related]
19. Effects of nadolol on systemic and renal hemodynamics in patients with renoparenchymal hypertension and various degrees of renal function.
Valvo E; Gammaro L; Bedogna V; Cavaggioni M; Tonon M; Lupo A; Loschiavo C; Tessitore N; Oldrizzi L; Rugiu G
Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):202-6. PubMed ID: 3710633
[TBL] [Abstract][Full Text] [Related]
20. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
